Atlas Capital Advisors Inc. Has $1.02 Million Stake in HCA Healthcare, Inc. (NYSE:HCA)

Atlas Capital Advisors Inc. decreased its stake in HCA Healthcare, Inc. (NYSE:HCA) by 38.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,395 shares of the company’s stock after selling 2,149 shares during the period. Atlas Capital Advisors Inc.’s holdings in HCA Healthcare were worth $1,019,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Magellan Asset Management Ltd increased its position in shares of HCA Healthcare by 1.3% during the fourth quarter. Magellan Asset Management Ltd now owns 527,774 shares of the company’s stock worth $158,411,000 after buying an additional 6,740 shares during the period. Pitcairn Co. raised its position in shares of HCA Healthcare by 5.6% in the 4th quarter. Pitcairn Co. now owns 3,725 shares of the company’s stock worth $1,118,000 after acquiring an additional 197 shares in the last quarter. Motley Fool Asset Management LLC grew its stake in HCA Healthcare by 14.4% during the fourth quarter. Motley Fool Asset Management LLC now owns 13,985 shares of the company’s stock worth $4,198,000 after purchasing an additional 1,757 shares during the period. Westpac Banking Corp lifted its stake in HCA Healthcare by 5.6% in the fourth quarter. Westpac Banking Corp now owns 24,706 shares of the company’s stock valued at $7,416,000 after buying an additional 1,302 shares during the period. Finally, OneAscent Financial Services LLC increased its stake in shares of HCA Healthcare by 15.0% in the 4th quarter. OneAscent Financial Services LLC now owns 2,157 shares of the company’s stock valued at $647,000 after acquiring an additional 282 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Stock Up 0.6 %

HCA opened at $349.03 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. The stock has a market cap of $85.93 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 1.10 and a beta of 1.68. The company’s 50-day moving average price is $326.83 and its two-hundred day moving average price is $340.36. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $417.14.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period last year, the firm earned $5.90 EPS. As a group, equities analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 17th were issued a dividend of $0.72 per share. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. The ex-dividend date was Monday, March 17th. This represents a $2.88 dividend on an annualized basis and a yield of 0.83%. HCA Healthcare’s payout ratio is presently 13.11%.

Insider Transactions at HCA Healthcare

In related news, SVP Jennifer Berres sold 9,533 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the completion of the transaction, the senior vice president now owns 15,412 shares of the company’s stock, valued at approximately $4,971,757.08. The trade was a 38.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HCA. Truist Financial decreased their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Barclays reduced their price objective on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. KeyCorp reduced their price target on shares of HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Morgan Stanley dropped their price objective on shares of HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of HCA Healthcare in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $385.67.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.